Anke Maes

583 total citations
21 papers, 393 citations indexed

About

Anke Maes is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Anke Maes has authored 21 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Hematology and 5 papers in Oncology. Recurrent topics in Anke Maes's work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers) and Ubiquitin and proteasome pathways (6 papers). Anke Maes is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers) and Ubiquitin and proteasome pathways (6 papers). Anke Maes collaborates with scholars based in Belgium, France and United Kingdom. Anke Maes's co-authors include Elke De Bruyne, Eline Menu, Kim De Veirman, Karin Vanderkerken, Ken Maes, Jérôme Moreaux, Philip Vlummens, Dirk Hose, Alboukadel Kassambara and Rong Fan and has published in prestigious journals such as Blood, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Anke Maes

20 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anke Maes Belgium 13 284 114 104 76 66 21 393
Kaosheng Lv China 12 295 1.0× 84 0.7× 89 0.9× 51 0.7× 61 0.9× 18 409
Lisa M. Privette Vinnedge United States 13 544 1.9× 38 0.3× 160 1.5× 38 0.5× 79 1.2× 28 639
Rashid Gabbasov United States 10 286 1.0× 66 0.6× 158 1.5× 91 1.2× 60 0.9× 21 525
Somsundar Veppil Muralidharan Sweden 9 451 1.6× 85 0.7× 134 1.3× 54 0.7× 106 1.6× 12 525
Michaël H. Meel Netherlands 13 172 0.6× 52 0.5× 68 0.7× 50 0.7× 65 1.0× 20 367
Sanket S. Acharya United States 5 441 1.6× 49 0.4× 95 0.9× 42 0.6× 194 2.9× 8 531
Barbara Mojsa United Kingdom 8 300 1.1× 28 0.2× 106 1.0× 89 1.2× 36 0.5× 10 368
Purnima K. Wagh United States 9 286 1.0× 20 0.2× 136 1.3× 103 1.4× 40 0.6× 11 449
Charis A. Venditti United States 7 258 0.9× 55 0.5× 79 0.8× 86 1.1× 42 0.6× 9 354
Erin D. Lucas Australia 8 163 0.6× 27 0.2× 125 1.2× 160 2.1× 73 1.1× 9 372

Countries citing papers authored by Anke Maes

Since Specialization
Citations

This map shows the geographic impact of Anke Maes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Maes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Maes more than expected).

Fields of papers citing papers by Anke Maes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Maes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Maes. The network helps show where Anke Maes may publish in the future.

Co-authorship network of co-authors of Anke Maes

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Maes. A scholar is included among the top collaborators of Anke Maes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Maes. Anke Maes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ates, Gamze, Sylvia Faict, Philip Vlummens, et al.. (2023). Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. The Journal of Pathology. 260(2). 112–123. 12 indexed citations
2.
Fan, Rong, Philip Vlummens, Anke Maes, et al.. (2023). Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. Journal for ImmunoTherapy of Cancer. 11(1). e005319–e005319. 12 indexed citations
3.
Deschoemaeker, Sofie, Geert Raes, Anke Maes, et al.. (2022). Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. International Journal of Molecular Sciences. 23(2). 904–904. 30 indexed citations
4.
Vlummens, Philip, Anke Maes, Dirk Hose, et al.. (2022). Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. Journal of Experimental & Clinical Cancer Research. 41(1). 45–45. 26 indexed citations
5.
Fan, Rong, Nathan De Beule, Anke Maes, et al.. (2022). The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Frontiers in Immunology. 13. 1016059–1016059. 15 indexed citations
6.
Vlummens, Philip, Rong Fan, Jennifer M. Knight, et al.. (2022). Targeting the β 2 ‐adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism. The Journal of Pathology. 259(1). 69–80. 13 indexed citations
7.
Vlummens, Philip, Stefaan Verhulst, Kim De Veirman, et al.. (2022). Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach. Frontiers in Cell and Developmental Biology. 10. 879057–879057. 5 indexed citations
8.
Maes, Anke, et al.. (2022). Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?. Frontiers in Oncology. 12. 979569–979569. 9 indexed citations
9.
Maes, Anke, Philip Vlummens, Elke De Bruyne, et al.. (2022). System Xc− inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. Cancer Letters. 535. 215649–215649. 22 indexed citations
10.
Ates, Gamze, Sylvia Faict, Philip Vlummens, et al.. (2022). Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis. Blood. 140(Supplement 1). 7078–7079.
11.
Maes, Anke, et al.. (2022). Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. Experimental Hematology and Oncology. 11(1). 49–49. 12 indexed citations
12.
Vieito, María, Anna Spreafico, Víctor Moreno, et al.. (2020). 537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers. Annals of Oncology. 31. S470–S470. 19 indexed citations
13.
Boussac, Hugues de, Angélique Bruyer, Michel Jourdan, et al.. (2019). Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica. 105(3). 784–795. 34 indexed citations
14.
Maes, Anke, Ken Maes, Philip Vlummens, et al.. (2019). Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal. 9(12). 87–87. 11 indexed citations
15.
Maes, Anke, Ken Maes, Hendrik De Raeve, et al.. (2019). The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer. 120(12). 1137–1146. 12 indexed citations
16.
Veirman, Kim De, Eline Menu, Ken Maes, et al.. (2018). Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters. 442. 233–241. 48 indexed citations
17.
Smedt, Eva De, Ken Maes, Stefaan Verhulst, et al.. (2017). Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. Cancer Research. 78(5). 1155–1168. 30 indexed citations
18.
Smedt, Eva De, Ken Maes, Stefaan Verhulst, et al.. (2016). RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma. Blood. 128(22). 2057–2057. 2 indexed citations
19.
Maes, Anke, Ken Maes, Kim De Veirman, et al.. (2015). Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 7(4). 4062–4076. 39 indexed citations
20.
Maes, Anke, Ken Maes, Kim De Veirman, et al.. (2014). Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma. Blood. 124(21). 2097–2097. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaosheng Lv Breakdown of academic impact, for papers by Lisa M. Privette Vinnedge Breakdown of academic impact, for papers by Rashid Gabbasov Breakdown of academic impact, for papers by Somsundar Veppil Muralidharan Breakdown of academic impact, for papers by Michaël H. Meel Breakdown of academic impact, for papers by Sanket S. Acharya Breakdown of academic impact, for papers by Barbara Mojsa Breakdown of academic impact, for papers by Purnima K. Wagh Breakdown of academic impact, for papers by Charis A. Venditti Breakdown of academic impact, for papers by Erin D. Lucas
Rankless by CCL
2026